I-Nov is France 2030’s highest-volume startup innovation competition and the primary entry point for early-stage deeptech companies into the French public funding ecosystem. Since 2021, I-Nov has funded over 1,500 startups across 13 thematic challenges and three annual waves, distributing approximately €1.5 billion in grants and repayable advances to France’s most promising young technology companies. It is the competition that has done most to establish France as Europe’s leading deeptech startup nation.

The Architecture of I-Nov

I-Nov (Innovation en entreprise) operates through a distinctive structural design that separates it from conventional grant competitions. Rather than accepting applications across all technology domains simultaneously, I-Nov organizes each wave around 13 specific thematic challenges — predefined problem areas where France 2030 seeks breakthrough solutions. This structure focuses competitive energy, improves evaluation quality, and ensures that funded projects address genuine strategic priorities rather than simply demonstrating technical novelty.

The 13 current I-Nov challenges span:

1. Artificial Intelligence and Data — Foundation models, applied AI, data infrastructure
2. Cybersecurity — Zero-trust architectures, post-quantum cryptography, OT security
3. Digital Transformation — Industry 4.0, digital twins, embedded systems
4. Deeptech Health — Medical devices, diagnostics, digital therapeutics, biotech
5. Bioproduction and Biotechnology — Fermentation, synthetic biology, biobased materials
6. Energy Transition — Clean energy production, storage, grid technology
7. Hydrogen — Electrolysis, storage, transportation, end-use applications
8. Electric Mobility — Battery technology, charging, software-defined vehicles
9. New Materials — Advanced composites, semiconductor materials, functional coatings
10. Agriculture and Food — Agritech, alternative proteins, precision farming
11. Space and New Space — Satellite systems, launchers, downstream applications
12. Defense and Dual-Use — Co-managed with DGA for technologies with civil and defense applications
13. Deep Tech Cross-Sector — Breakthrough technologies that do not fit neatly into a single challenge

Funding Ranges and Conditions

I-Nov provides two categories of financial support:

Grants (Subventions): Non-repayable. Available for the “innovative studies” component of a project — typically early-stage validation, prototype development, or market analysis. Range: €100,000 to €600,000 per project.

Repayable Advances (Avances Remboursables): The primary I-Nov instrument. Range: €500,000 to €3.5 million per project, with total award per company capped at €4 million in any single wave. Repayment is triggered when the funded project generates revenue exceeding a threshold set in the funding contract (typically €5 million in cumulative revenue from the technology developed). If the commercial threshold is never reached within 10 years, the advance is forgiven.

The combination of grant and repayable advance in a single I-Nov award — often structured as 30% grant, 70% repayable advance — reflects the program’s design logic: public money takes the research risk (grant component) but participates in upside through repayment when the technology commercializes (advance component).

Co-financing requirement: I-Nov applicants must secure private co-financing equal to at least 30% of total project costs. For earlier-stage startups, this may be met with existing investor commitments. Unlike I-Démo, I-Nov does not require the co-financing to be fully committed at application — a letter of intent from a lead investor is typically sufficient.

The Three Annual Waves: Scale and Selection

I-Nov runs three waves annually — typically January, May, and September deadlines. Each wave processes approximately 1,000 applications per wave, with 13 thematic panels evaluating between 50 and 200 applications per challenge.

Application volumes by sector (approximate share of total applications):

• AI and data: 22%
• Health and biotech: 18%
• Energy transition and cleantech: 15%
• Mobility and batteries: 12%
• Cybersecurity and digital: 10%
• Other challenges: 23% combined

Overall success rate: 12 to 15% of admissible applications receive funding. Challenge-level variation is significant: the hydrogen challenge has historically had the highest success rates (20-25%) because applications are more technically specialized and self-selection is stronger. AI applications have the lowest success rate (8-12%) due to the sheer volume and the difficulty of differentiating genuinely novel approaches from incremental improvements.

Number of winners per wave: Approximately 250 to 350 per wave, across all 13 challenges. Total winners since 2021: over 1,500 distinct companies.

I-Nov Alumni: The Track Record

The I-Nov alumni portfolio has produced an exceptional set of outcomes that validate the program’s design. Among companies that received I-Nov awards between 2021 and 2024:

Companies that raised €50 million-plus after I-Nov:

• Beyond Aero — Hydrogen-electric aircraft startup. I-Nov Wave 1 winner, subsequently raised €25 million Series A
• Wandercraft — Exoskeleton for medical rehabilitation. I-Nov health winner, raised €45 million
• Atawey — Hydrogen refueling station technology. I-Nov hydrogen winner, expanded to European deployment
• Poolside — AI code generation. I-Nov AI winner before its $500 million Series B
• H2X — Green hydrogen for industrial decarbonization. Multiple I-Nov awards
• Naarea — Molten salt micro-reactor. I-Nov deeptech winner, subsequently raised €20 million

Notable 2023-2024 winners include Sweetch Energy (osmotic energy from river-sea mixing), Nucleia (AI-powered nuclear waste characterization), Ombrea (agrivoltaics), and Volta Medical (AI-guided cardiac ablation).

The survival rate of I-Nov winners is substantially higher than the French startup average. Bpifrance’s internal assessment suggests 72% of I-Nov 2021-2022 cohort companies are still operating with revenue activity as of 2025, compared to a national startup 3-year survival rate of approximately 55%.

The Evaluation Process

Pre-diagnosis: Unlike I-Démo, I-Nov does not offer formal pre-diagnosis consultations. However, Bpifrance’s regional offices (one in each French département) provide informal guidance sessions that help applicants assess fit.

Stage 1 — Admissibility: Automated check of eligibility criteria completion and document compliance. Approximately 15% of applications are rejected at this stage for administrative incompleteness.

Stage 2 — Expert Panel Review: Each admissible application is reviewed by 2 to 3 independent experts with sector-specific expertise. Reviewers score on a standardized rubric covering: technical innovation level, market potential, team quality, environmental alignment, and project execution plan. Scorecards are confidential but aggregated scores determine ranking.

Stage 3 — Investment Committee: The top-ranked applications within each challenge go to a Bpifrance Investment Committee that makes final selection decisions. For borderline cases, applicants may be invited to present (by video) for 20 minutes.

Timeline: Application submission to funding decision: 4 to 6 months. Contract signature and first disbursement: typically 2 months after decision.

Application Strategy: What I-Nov Evaluators Are Looking For

Based on published evaluation criteria and the revealed preferences of the selection system, successful I-Nov applications share several characteristics:

Technology specificity: Evaluators respond to precise technical claims backed by prototype data or scientific validation, not broad descriptions of a technology category. “We are building an AI system” fails. “We have achieved 94% accuracy on X benchmark using our novel transformer variant Y, outperforming the state of the art by 12 percentage points” succeeds.

Market sizing with evidence: A €10 billion total addressable market claim without basis is a red flag. A €800 million serviceable market backed by industry data, named customer pilots, and a credible go-to-market timeline is compelling.

French industrial anchoring: Projects that explicitly link to the French industrial ecosystem — named French manufacturing partners, French customer pilots, plans for French hiring — consistently outperform equivalent applications that do not make the domestic connection.

Team depth: Early-stage companies with a technical founder and a commercially experienced co-founder score significantly higher than single-founder technical teams without commercial development capacity.

I-Nov and the French Tech Ecosystem

I-Nov functions as more than a funding competition. It is a credential. An I-Nov award signals to private investors that a startup has passed rigorous public evaluation — a certification that accelerates fundraising conversations, particularly with institutional VCs who track Bpifrance selection decisions.

Bpifrance data shows that I-Nov winners raise private capital at 3.2x the rate of comparable startups that applied but were not selected. The award also unlocks preferential access to other Bpifrance support: innovation loans, equity co-investment, export guarantees. An I-Nov win opens doors across the entire Bpifrance ecosystem.

The aggregate effect: I-Nov is not simply distributing €300 million per year in grants. It is systematically identifying the top 12 to 15% of French deeptech startups and routing preferential capital, network access, and credibility to those companies — creating a compounding selection advantage for the French deeptech ecosystem relative to European competitors.